CDMO Sterling Pharma Solutions has acquired UK-based NewChem Technologies, which offers contract services focused on complex organic process chemistry to the pharmaceuticals, chemicals, diagnostics, biotechnology and veterinary markets. Terms were not disclosed, but the deal includes all of NewChem’s assets and employees.
Global Healthcare Opportunities (GHO), a European specialist investor in healthcare, and Partners Group, a global private markets firm, have both invested in Sterling Pharma Solutions, a CDMO owned by GHO. The exact amounts have not been disclosed.
UK-based CDMO Sterling Pharma Solutions has completed the acquisition of Novartis’ API facility in Ringaskiddy, near Cork, Ireland. The deal includes an on-going supply agreement to make APIs for cardiovascular, immunology and oncology medicines for Novartis. No financial details were disclosed.
CDMO Sterling Pharma Solutions has agreed to acquire Novartis’s 45-hectare Ringaskiddy campus near Cork, Ireland. Financial details of the sale, which is expected to close in Q4, 2022, have not been disclosed. All of the workforce will transfer to Sterling, bringing its global total to over 1,000.
The deal also includes an ongoing supply agreement for products Novartis has made at the site. The facilities include three API manufacturing buildings, plus facilities to support development and scale-up.
Following on from earlier acquisitions and investments on both sides of the Atlantic, Sterling Pharma Solutions has commenced a $2.1 million expansion project to increase chemical and analytical capabilities at its facility in Cary, North Carolina. The work should be completed by the end of 2022 and will create up to 20 new jobs. This will include five new laboratories: two for R&D, one for scaling up chemical synthesis and others for QC and analytical services.
CDMO Sterling Pharma Solutions has announced what it called the next phase of a multi-year investment strategy at its site in Dudley, UK. It will spend £10 million by mid-2022 on new process development laboratories and commercial-scale manufacturing equipment to meet growth in demand for small molecule API manufacturing.
CDMO Sterling Pharma Solutions has completed the initial phase of investment in its centre of excellence for research into the commercial applications of continuous flow chemistry at Dudley, UK. This follows the appointment in July of Professor Ian Baxendale of Durham University to head a dedicated team in this field.